Cancer Vaccine: After the Drugs Controller General of India's (DCGI) approval, the Serum Institute of India (SII) is all set to launch its indigenously-developed cervical cancer vaccine later this year.
According to SII, the Quadrivalent Human Papillomavirus vaccine (qHPV) to treat cervical cancer in women will be affordable and accessible.
Cervical cancer in India ranks as the second-most frequent cancer among women between 15 and 44 years of age. The vaccine is based on VLP (virus-like particles), similar to the Hepatitis B vaccine and protects by generating antibodies against the HPV virus L1 protein.
The trials for the vaccine started in 2019 and thousands of participants in the age group of 9‐26 years were part of the trials across India. Phase three results showed a robust immune response in 100 per cent of the vaccine recipients with good safety records.
Also watch: Researchers develop a new single-shot vaccine to cure AIDS